These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 26947200)

  • 1. Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study.
    Green ML; Leisenring W; Xie H; Mast TC; Cui Y; Sandmaier BM; Sorror ML; Goyal S; Özkök S; Yi J; Sahoo F; Kimball LE; Jerome KR; Marks MA; Boeckh M
    Lancet Haematol; 2016 Mar; 3(3):e119-27. PubMed ID: 26947200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A novel therapeutic cytomegalovirus DNA vaccine in allogeneic haemopoietic stem-cell transplantation: a randomised, double-blind, placebo-controlled, phase 2 trial.
    Kharfan-Dabaja MA; Boeckh M; Wilck MB; Langston AA; Chu AH; Wloch MK; Guterwill DF; Smith LR; Rolland AP; Kenney RT
    Lancet Infect Dis; 2012 Apr; 12(4):290-9. PubMed ID: 22237175
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cytomegalovirus pre-emptive therapy after hematopoietic stem cell transplantation in the era of real-time quantitative PCR: comparison with recipients of solid organ transplants.
    Panagou E; Zakout G; Keshani J; Smith C; Irish D; Mackinnon S; Kottaridis P; Fielding A; Griffiths PD
    Transpl Infect Dis; 2016 Jun; 18(3):405-14. PubMed ID: 27061703
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viraemia, immunogenicity, and survival outcomes of cytomegalovirus chimeric epitope vaccine supplemented with PF03512676 (CMVPepVax) in allogeneic haemopoietic stem-cell transplantation: randomised phase 1b trial.
    Nakamura R; La Rosa C; Longmate J; Drake J; Slape C; Zhou Q; Lampa MG; O'Donnell M; Cai JL; Farol L; Salhotra A; Snyder DS; Aldoss I; Forman SJ; Miller JS; Zaia JA; Diamond DJ
    Lancet Haematol; 2016 Feb; 3(2):e87-98. PubMed ID: 26853648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis.
    Bartelink IH; Lalmohamed A; van Reij EM; Dvorak CC; Savic RM; Zwaveling J; Bredius RG; Egberts AC; Bierings M; Kletzel M; Shaw PJ; Nath CE; Hempel G; Ansari M; Krajinovic M; Théorêt Y; Duval M; Keizer RJ; Bittencourt H; Hassan M; Güngör T; Wynn RF; Veys P; Cuvelier GD; Marktel S; Chiesa R; Cowan MJ; Slatter MA; Stricherz MK; Jennissen C; Long-Boyle JR; Boelens JJ
    Lancet Haematol; 2016 Nov; 3(11):e526-e536. PubMed ID: 27746112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for the development of cytomegalovirus disease after allogeneic stem cell transplantation.
    Ljungman P; Perez-Bercoff L; Jonsson J; Avetisyan G; Sparrelid E; Aschan J; Barkholt L; Larsson K; Winiarski J; Yun Z; Ringdén O
    Haematologica; 2006 Jan; 91(1):78-83. PubMed ID: 16434374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytomegalovirus Reactivation after Allogeneic Hematopoietic Stem Cell Transplantation is Associated with a Reduced Risk of Relapse in Patients with Acute Myeloid Leukemia Who Survived to Day 100 after Transplantation: The Japan Society for Hematopoietic Cell Transplantation Transplantation-related Complication Working Group.
    Takenaka K; Nishida T; Asano-Mori Y; Oshima K; Ohashi K; Mori T; Kanamori H; Miyamura K; Kato C; Kobayashi N; Uchida N; Nakamae H; Ichinohe T; Morishima Y; Suzuki R; Yamaguchi T; Fukuda T
    Biol Blood Marrow Transplant; 2015 Nov; 21(11):2008-16. PubMed ID: 26211985
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Donor Genotype in the Interleukin-7 Receptor α-Chain Predicts Risk of Graft-versus-Host Disease and Cytomegalovirus Infection after Allogeneic Hematopoietic Stem Cell Transplantation.
    Kielsen K; Enevold C; Heilmann C; Sengeløv H; Pedersen AE; Ryder LP; Müller K
    Front Immunol; 2018; 9():109. PubMed ID: 29456530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose acyclovir and pre-emptive ganciclovir in prevention of cytomegalovirus disease in pediatric patients following peripheral blood stem cell transplantation.
    Hazar V; Kansoy S; Küpesiz A; Aksoylar S; Kantar M; Yeşilipek A
    Bone Marrow Transplant; 2004 May; 33(9):931-5. PubMed ID: 15034541
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vorinostat plus tacrolimus and mycophenolate to prevent graft-versus-host disease after related-donor reduced-intensity conditioning allogeneic haemopoietic stem-cell transplantation: a phase 1/2 trial.
    Choi SW; Braun T; Chang L; Ferrara JL; Pawarode A; Magenau JM; Hou G; Beumer JH; Levine JE; Goldstein S; Couriel DR; Stockerl-Goldstein K; Krijanovski OI; Kitko C; Yanik GA; Lehmann MH; Tawara I; Sun Y; Paczesny S; Mapara MY; Dinarello CA; DiPersio JF; Reddy P
    Lancet Oncol; 2014 Jan; 15(1):87-95. PubMed ID: 24295572
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Cytomegalovirus Viral Load on Probability of Spontaneous Clearance and Response to Preemptive Therapy in Allogeneic Stem Cell Transplantation Recipients.
    Camargo JF; Kimble E; Rosa R; Shimose LA; Bueno MX; Jeyakumar N; Morris MI; Abbo LM; Simkins J; Alencar MC; Benjamin C; Wieder E; Jimenez A; Beitinjaneh A; Goodman M; Byrnes JJ; Lekakis LJ; Pereira D; Komanduri KV
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):806-814. PubMed ID: 29217388
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytomegalovirus viral load parameters associated with earlier initiation of pre-emptive therapy after solid organ transplantation.
    Lumley S; Green C; Rafferty H; Smith C; Harber M; O'Beirne J; Jones G; Thorburn D; Marshall A; Shah T; Zuhair M; Rothwell E; Atabani S; Haque T; Griffiths P
    PLoS One; 2019; 14(1):e0210420. PubMed ID: 30682032
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytomegalovirus diseases after allogeneic hematopoietic stem cell transplantation (Allo-HSCT) and related risk factors].
    Huang XJ; Xu LP; Ren HY; Zhang YC; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 May; 83(9):766-9. PubMed ID: 12899755
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Factors Associated with Survival Following Ganciclovir Prophylaxis through Day +100 in Cytomegalovirus At-Risk Pediatric Allogeneic Stem Cell Transplantation Recipients: Development of Cytomegalovirus Viremia Associated with Significantly Decreased 1-Year Survival.
    Klejmont LM; Mo X; Milner J; Harrison L; Morris E; van de Ven C; Cairo MS
    Transplant Cell Ther; 2024 Jan; 30(1):103.e1-103.e8. PubMed ID: 37806447
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Maribavir prophylaxis for prevention of cytomegalovirus disease in recipients of allogeneic stem-cell transplants: a phase 3, double-blind, placebo-controlled, randomised trial.
    Marty FM; Ljungman P; Papanicolaou GA; Winston DJ; Chemaly RF; Strasfeld L; Young JA; Rodriguez T; Maertens J; Schmitt M; Einsele H; Ferrant A; Lipton JH; Villano SA; Chen H; Boeckh M;
    Lancet Infect Dis; 2011 Apr; 11(4):284-92. PubMed ID: 21414843
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors and incidence of cytomegalovirus viremia and disease in pediatric patients with allogeneic hematopoietic stem cell transplantation: An 8-year single-center experience in Latin America.
    Aristizabal AM; Perez P; Patiño Niño JA; Franco A; Tarapues EM; Beltran E; Medina D
    Pediatr Transplant; 2022 Sep; 26(6):e14324. PubMed ID: 35647735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Patients with refractory cytomegalovirus (CMV) infection following allogeneic haematopoietic stem cell transplantation are at high risk for CMV disease and non-relapse mortality.
    Liu J; Kong J; Chang YJ; Chen H; Chen YH; Han W; Wang Y; Yan CH; Wang JZ; Wang FR; Chen Y; Zhang XH; Xu LP; Liu KY; Huang XJ
    Clin Microbiol Infect; 2015 Dec; 21(12):1121.e9-15. PubMed ID: 26093077
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Molecular monitoring of adenovirus reactivation in faeces after haematopoietic stem-cell transplantation to predict systemic infection: a retrospective cohort study.
    Hum RM; Deambrosis D; Lum SH; Davies E; Bonney D; Guiver M; Turner A; Wynn RF; Hiwarkar P
    Lancet Haematol; 2018 Sep; 5(9):e422-e429. PubMed ID: 30172346
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical and financial burden of pre-emptive management of cytomegalovirus disease after allogeneic stem cell transplantation-implications for preventative treatment approaches.
    Jain NA; Lu K; Ito S; Muranski P; Hourigan CS; Haggerty J; Chokshi PD; Ramos C; Cho E; Cook L; Childs R; Battiwalla M; Barrett AJ
    Cytotherapy; 2014 Jul; 16(7):927-33. PubMed ID: 24831837
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.